Vision, Integrity, Expertise
Soligenix, Inc. is a development stage biopharmaceutical company committed to developing products to treat life-threatening side effects of cancer treatments and serious gastrointestional diseases, and vaccines for certain bioterrorism agents. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as pediatric Crohn’s disease, acute radiation enteritis, and Graft-versus-Host disease (GVHD), and 2) a vaccine/biodefense segment to develop vaccines and therapeutics for military and civilian applications.
Latest News
Monday, May 14, 2012
Soligenix Reports First Quarter 2012 Financial Results and Highlights Recent AccomplishmentsWednesday, April 25, 2012
Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStabilityWednesday, March 28, 2012
Soligenix Reports Year-End 2011 Financial Results and Highlights Recent AccomplishmentsPartnering with Us
Soligenix is interested in identifying new partnership and merger opportunities for its existing products as well as new in-licensing candidates in the areas of HSC transplant, supportive cancer care, gastrointestinal and biodefense.